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Abstract
3-Phosphoinositide–dependent protein kinase 1 (PDK1) is the pivotal element of the phosphatidylinositol 3 kinase
(PI3K) signaling pathway because it phosphorylates Akt/PKB through interactions with phosphatidylinositol
3,4,5 phosphate. Recent data indicate that PDK1 is overexpressed in many breast carcinomas and that alterations
of PDK1 are critical in the context of oncogenic PI3K activation. However, the role of PDK1 in tumor progression is
still controversial. Here, we show that PDK1 is required for anchorage-independent and xenograft growth of breast
cancer cells harboring either PI3KCA or KRAS mutations. In fact, PDK1 silencing leads to increased anoikis, re-
duced soft agar growth, and pronounced apoptosis inside tumors. Interestingly, these phenotypes are reverted
by PDK1 wild-type but not kinase-dead mutant, suggesting a relevant role of PDK1 kinase activity, even if PDK1
is not relevant for Akt activation here. Indeed, the expression of constitutively active forms of Akt in PDK1 knock-
down cells is unable to rescue the anchorage-independent growth. In addition, Akt down-regulation and pharma-
cological inhibition do not inhibit the effects of PDK1 overexpression. In summary, these results suggest that PDK1
may contribute to breast cancer, even in the absence of PI3K oncogenic mutations and through both Akt-dependent
and Akt-independent mechanisms.
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Introduction
The phosphatidylinositol 3 kinase (PI3K) pathway is one of the most
important pathways in cancer metabolism and growth [1,2]. Class IA
PI3Ks, deregulated in cancer, are heterodimers composed of a regu-
latory (p85) and a catalytic (p110) subunit. Binding of p85 to tyro-
sine kinase receptors removes the inhibitory effect of p85 on p110,
resulting in the full activation of PI3K. The activated kinase catalyzes
the phosphorylation of phosphatidylinositol 4,5 biphosphate to
phosphatidylinositol 3,4,5 triphosphate (PIP3). PIP3 acts as a dock-
ing site for 3-phosphoinositide–dependent kinase 1 (PDK1) and Akt
that, in turn, phosphorylates their substrates, including mammalian
target of rapamycin and glycogen synthase kinase β (GSK3β) [3].
PDK1 is a cytoplasmic kinase that phosphorylates serine/threonine
residues in the activation segment of AGC (cAMP-dependent protein
kinases A, cGMP-dependent protein kinases G, and phospholipid-
dependent protein kinases C) family protein, initially discovered as
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the kinase that phosphorylates Akt on threonine 308 upon binding to
PIP3 [4–6]. In fact, PDK1 is able to recognize the phosphoinositides
phosphorylated in position 3 by PI3K, through its C-terminal pleck-
strin homology (PH) domain. This event localizes PDK1 to the plasma
membrane where it phosphorylates Akt [6]. PDK1 substrates lacking
the PH domain, such as p70S6K [7], SGK [8], RSK [9], and PKC iso-
forms [10], require a different mechanism for their activation: PDK1,
through its PIF-binding pocket, binds the hydrophobic motif on these
substrates, and this leads to their phosphorylation and full activation
[4,11]. Furthermore, it has been described that PDK1 binds and reg-
ulates other substrates through kinase-independent mechanisms.
PDK1 has been demonstrated to activate the Ral guanine nucleotide
exchange factors through its noncatalytic N-terminal 50 amino acids
[12] and found to activate Rho-associated coiled-coil contain-
ing protein kinase 1 (ROCK1) by competing against its inhibitor
RhoE [13].
The PI3K pathway is often aberrantly activated in breast cancer
with mutations occurring in up to one quarter of breast cancers.
PIK3CA activating mutations and PTEN loss are the most frequent
events in human breast tumors, whereas a significant role for Akt1
mutations is also emerging [14]. Moreover, most of the elements
of this pathway are found hyperactive or amplified in breast tumors:
PIK3CA [15], PIK3CB [16], Akt1 [17], Akt2 [18], PDK1 [19],
p70S6 kinase [20], and IKBKE [21]. Such alterations strongly corre-
late with a more aggressive phenotype and a poor prognosis.
Recently, PDK1 was found overexpressed both at the protein and
mRNA levels in most human breast cancer with frequent genomic
amplifications. Moreover, its Ser-241 phosphorylated form was
found enriched in human breast carcinoma versus benign tumors
[22,23]. Despite this, forced PDK1 expression has been described
to be oncogenic only in the Comma-1D murine mammary cell model
[24,25], whereas in breast-derived cell lines, it is able to potentiate the
oncogenic effects of upstream lesions but not to transform per se [19].
In mice, its oncogenic effect seems to function by altering the PI3K
pathway because PTEN-driven tumors were severely attenuated in
PDK1 knockout and hypomorphic mice. However, results obtained
with human cancer cell lines [26] together with the involvement of
PDK1 in resistance mechanisms to several anticancer drugs such as
gemcitabine, trastuzumab, tamoxifen, and rapamicin suggest that
PDK1 regulates others oncogenic signaling pathways [27–30].
Here, we show that PDK1 regulates anchorage-independent
growth, resistance to anoikis, and tumor formation in breast cancer
cells not only harboring PIK3CA genetic alterations but also in the
absence of these lesions.
Materials and Methods
Cell Lines
293T (CRL-11268), MDA-MB-231 (HTB-26), and T-47D
(HTB-133) cell lines were obtained from ATCC resource center
(http://www.atcc.org). Phoenix-GP was provided by Garry P. Nolan
Lab (Stanford, CA). The MDA-MB-231 metastatic variant, LM2-
4175, was a gift from Dr. Joan Massagué (Sloan-Kettering Institute,
New York, NY) [31]. 293T, MDA-MB-231, and Phoenix-GP were
cultured in Dulbecco modified Eagle medium (DMEM; catalog no.
D5546; Sigma-Aldrich, St Louis, MO), whereas T-47D cells were cul-
tured in RPMI 1640medium (catalog no. R0883; Sigma-Aldrich). The
culture media were supplemented with 10% FBS (catalog no. 10270;
Gibco, Life Technologies, Rockville, MD) and 200 U/ml penicillin
and 200 μg/ml streptomycin (catalog no. 67513; Sigma-Aldrich).
Soft Agar Colony Formation Assay
One milliliter of bottom layer constituted by 0.7% agar (catalog
no. 214220; Becton Dickinson, Franklin Lakes, NJ) in DMEM was
spread in each 35-mm-diameter well. A total of 1 × 104 cells were
suspended in 3 ml of DMEM–10% FBS 0.35% agar and spread over
the bottom layer. A layer of medium (1.5 ml) was added on the gel
layers and substituted every 3 to 4 days until the end of the assay (15-
21 days). For the quantification, colonies grown in soft agar were
stained with nitrotetrazolium blue chloride (N-6876; Sigma-Aldrich).
High-resolution image acquisitions by ChemiDoc XRS (170-8070;
Bio-Rad Laboratories, Hercules, CA) were processed and analyzed
using the ImageJ software (http://rsbweb.nih.gov/ij/). Only colonies
with diameter bigger than 100 μm were counted.
Anoikis and Apoptosis Assay
For the anoikis assay, 4 × 105 MDA-MB-231 or T-47D were
seeded in 35-mm dishes coated with poly-hydroxy-ethyl-methacrylate
(catalog no. P3942; Sigma-Aldrich) in medium with 10% FBS. For
the apoptosis assay, 4 × 105 MDA-MB-231 or T-47D were seeded in
35-mm dishes in the absence of FBS. After 2 days, the percentage of
apoptotic cells was evaluated by FACS analysis using M30 Cyto-
DEATH (12-140-349-001; Roche Applied Science, Indianapolis,
IN), or alternatively, the rate of apoptosis was evaluated using Cell
Death Detection ELISAplus (11-774-425-001; Roche).
Xenograft Assay
MDA-MB-231 cells were inoculated subcutaneously in nude
athymic mice (5 × 106 cells) or in NOD/SCID mice (3 × 106 cells).
After 30 days, mice were killed, and tumor weight was evaluated.
The tumors were cryopreserved by OCT embedding at −80°C. Cryo-
sections of 15 μm thickness were stained with In Situ Cell Death
Detection Kit, TMR red (12-156-792-910; Roche) for the evaluation
of apoptotic cells.
Statistical Analysis
Data were compared using a Student’s t test. Results were expressed
as mean and SD of at least three independent experiments each in
triplicate. The EC50 of log[inhibitor]-versus-response curves was cal-
culated with the nonlinear regression tool of the GraphPad 5 Prism
software (GraphPad, La Jolla, CA).
PDK1, Akt, and PI3K Inhibitors
BX-795 (catalog no. 1390; Axon Medchem, Groningen, the
Netherlands), OSU-03012 (catalog no. 1-800-364-9897; Cayman
Chemical, Ann Arbor, MI), LY294002 (catalog no. 9901; Cell Sig-
naling, Danvers, MA), and Akt inhibitor VIII (catalog no. 124017;
Calbiochem, Darmstadt, Germany) were reconstituted in DMSO at
10 mM. All the inhibitors were stored in small aliquots at −20°C and
thawed at the time of use.
PDK1 Mutants and Cloning into pCCL Lentiviral Vector
Myc-tagged PDK1, PDK1-KD (K110N), PDK1-ΔPH, and
PDK1-K465E previously cloned into PINCO retroviral vector [32]
were subcloned into a third-generation lentiviral vector pCCL
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sin.cPPT.PGK.GFP.WPRE [33] with In-Fusion 2.0-CF Dry-Down-
PCR Cloning-Kit (catalog no. 639607; Clontech Laboratories,
Mountain View, CA). For cloning, the following primers were de-
signed: “FW-rec-pCCL” (GGGGATCC CCCGGGCTGCAGATG-
GAGCAGAAGCTGATCAGCGAGGAGG), “RE-rec-pCCL”
(GAGGTTGATTGTCGACTCACTGCACAGCGGCGTCCGGG),
and “ΔPH-RE-rec-pCCL” (GAGGTTGATTGTCGACTCACT-
GGTGCCAAGGGTTTCCGCCAG). The acceptor plasmid pCCL
sin.cPPT.PGK.GFP.WPRE was digested in PstI and SalI sites. Dur-
ing cloning, two punctiform and silent substitutions were added to
PDK1 coding sequence to make it resistant to the shPDK1#79 short
hairpin RNA (shRNA) (TRCN0000039779) by using the following
primers: “RE-mut” (GCTTCTCCAACAACAAGCGCTTCTCAT-
CTTCGG) and “FW-mut” primers (CCGAAGATGAGAAGCGC-
TTGTTGTTGGAGAAGC).
Akt T308D S473D Cloning into pBABE-puro
Retroviral Vector
The bovine coding sequence of phosphomimetic Akt1 was cloned
from “HA PKB T308D S473D pcDNA3” (a gift from JimWoodgett;
Addgene plasmid no. 14751, Cambridge, MA). The cloning was ob-
tained by recombination using the In-Fusion 2.0-CF Dry-Down-PCR
Cloning-Kit. The acceptor plasmid pBABE-puro was digested with
BamHI and EcoRI, and the two primers used are as follows: “FW”
GGCGCCGGCCGAATCCATGTACCCATACGATGTTCCAG
and “RE” CTGTGCTGGCGAATTCTCAGGCCGTCGCGC.
Lentiviral Vector Production and Infection
For PDK1 stable silencing, two pLKO.1 lentiviral vectors carrying
PDK1 targeting shRNA called shPDK1#79 (TRCN0000039779;
Sigma-Aldrich) and shPDK1#81 (TRCN0000039781) were used,
respectively. For Akt1 and Akt2 the following vectors were used:
shAkt1#86 (TRCN0000039968), shAkt1#97 (TRCN0000039797),
shAkt2#17 (TRCN0000255917), and shAkt2#68 (TRCN0000039968).
A vector leading the expression of a scrambled not targeting shRNA,
called shScr (Sigma-Aldrich), and a vector targeting the green fluorescent
protein (GFP) construct (EGFP control vector; Sigma-Aldrich) were
used as negative controls. For the expression of PDK1 constructs, the
pCCL sin.cPPT.PGK.GFP.WPRE lentiviral vector [33] was used, lead-
ing the expression, through a bidirectional promoter, of both PDK1
constructs and GFP. As a negative control, a plasmid expressing only
GFP was used (empty vector). All viruses were produced as described
in the TRC shRNA guidelines. Infection of cells was performed with
a multiplicity of infection equal to 1 for pLKO.1 and multiplicity of
infection equal to 3 for pCCL sin.cPPT.PGK.GFP.WPRE in the pres-
ence of 8 μg/ml Polybrene (H-9268; Sigma-Aldrich). Cells infectedwith
pLKO.1 lentiviral vectors were selected with 2.5 μg/ml puromycin for
2 days, and the surviving cell population was used for the experiments.
Retroviral Vector Production and Infection
For Akt1 or Akt2 expression, the following retroviral vectors were
used: “pBABE puro” negative control vector (a gift fromBobWeinberg;
Addgene plasmid no. 1764); “pBABE myr-Akt1” (a gift from William
Hahn, Addgene plasmid no. 15294); “pBABE Akt1,” “pBABE myr-
Akt2,” “pLNCX Akt1,” and “pLNCX myr-Akt1,” “pLNCX myr-
Akt1 K179M” (gifts from William Sellers; Addgene plasmid nos.
9011, 9018, 9004, 9005, and 9006, respectively); and “pBABE Akt1
T308D S473D” (see cloning). For retroviral particles production,
Phoenix-GP cells were transfected with retroviral vector plasmid and
pMD2.G vector, expressing the VSV-G envelope. Collection and infec-
tion of retroviral particles were performed as described [32]. Infected
cells were selected using 2.5 μg/ml of puromycin (P7255; Sigma-
Aldrich) for pBABE vector vectors and 1 mg/ml Geneticin (catalog
no. 10131-027; Gibco) for pLNCX series vectors.
Immunoblot Analysis
Immunoblot analysis was performed as described [32]. The follow-
ing primary antibodies were used: PDK1 (no. 3062), pS241PDK1
(no. 3061), Akt1 (no. 2967), Akt2 (no. 2964), pT308Akt (no. 4056),
pS473Akt (no. 4060), pS9GSK3β (no. 9323), pFoxO1(Thr24)/
FoxO3a(Thr32)/FoxO4(Thr28) (no. 2599) from Cell Signaling and
γ-tubulin (sc-17787) and β-actin (sc-1616) from Santa Cruz Biotech-
nology (Santa Cruz, CA).
Proliferation Assay
The proliferation assay was performed as previously described [34].
Immunofluorescence
Cryosection from experimental tumors were fixed in 3.7% para-
formaldehyde pH 7.4 for 1 hour, washed three times with PBS, and
permeabilized for 1 hour in PBS 0.5% Triton X-100 (T8294; Sigma-
Aldrich) and 10% donkey serum (D9663; Sigma-Aldrich). The pri-
mary antibodies were left on the slices overnight in PBS 10% donkey
serum at 1:100 dilution at 4°C. The secondary staining was per-
formed at 25°C for 1 hour with fluorescent dye–conjugated anti-
bodies (Alexa Fluor series; Invitrogen, Carlsbad, CA). The images
were acquired with a confocal laser scanning microscope (TCS SP2
with DM IRE2; Leica Microsystems, Wetzlar, Germany) equipped
with 20×, 40×, and 63×/1.40 HCX Plan-Apochromat oil immersion
objective. Confocal images are the maximum-intensity projections of
the complete z section. The immunostaining signal was quantified
using the ImageJ Software. The primary antibodies used are as fol-
lows: anti–Ki-67 (MAB4190; Millipore), anti-CD31 (553370; BD,
Franklin Lakes, NJ), anti-Akt1 (no. 2967; Cell signaling), anti-
pT308Akt (no. 4056; Cell Signaling), anti-PDK1 (611070; BD),
and anti-pS241PDK1 (no. 3061; Cell Signaling).
Results
PDK1 Is Required for Anchorage-Independent Growth in
Breast Cancer Cells
To evaluate the role of PDK1 in breast cancer, we stably down-
regulated it in human mammary tumor cell lines harboring different
genetic lesions. MDA-MB-231 cells are mutated for KRAS (G13D),
whereas T-47D cells harbor a mutation in the PI3K (H1047R)
catalytic domain. Specifically, we transduced MDA-MB-231 and
T-47D cells with shRNAs for PDK1 (shPDK1#79 and shPDK1#81)
by a lentiviral-mediated based approach. PDK1 knockdown cells
exhibited low levels of PDK1 compared to cells transduced with a
nontargeting construct (shScr) and uninfected cells (Figure 1, A and
B). Apparently, the reduced level of PDK1 did not modify the ability
of both MDA-MB-231 and T-47D to the growth on plastic culture
dishes (Figure W1, A and B ). However, when grown in soft agar,
the PDK1-silenced cell lines exhibited reduced anchorage-independent
growth ability (Figure 1, C andD). Interestingly, both cell lines require
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PDK1 to grow in the absence of anchorage irrespective of their different
origin and genetic lesions.
PDK1 Down-regulation Increases Sensitivity to Anoikis and
Serum Deprivation
A common feature of malignant transformation is the ability to
evade apoptotic cell death signals, such as lack of growth factors. Fur-
thermore, tumor cells are often resistant to anoikis, the process of
apoptosis induced by cell matrix detachment. T-47D and MDA-
MB-231 are particularly resistant to anoikis; in fact, the number of
apoptotic cells after 48 hours of growth in suspension is less than 4%
and 10%, respectively. PDK1 silencing strongly increased the cells’
susceptibility to apoptosis in the absence of anchorage, evaluated
both as caspase 3 activation (Figure 1, E and F ) and as number of
oligonucleosomes (Figure W1, C and D ). PDK1 down-modulation
also increased apoptosis induced by serum deprivation in adherent
cells, which was particularly evident in MDA-MB-231 cells
(Figure W1E ) compared with T-47D (Figure W1F ).
In Vivo Tumor Growth Is Reduced by PDK1 Knockdown
To further analyze the role of PDK1 in tumorigenesis, we injected
PDK1 knockdown and control MDA-MB-231 cells into immuno-
deficient mice. ShPDK1#79- and shPDK1#81-expressing tumors
grew significantly slower than did control tumors expressing shScr
(Figure 2A ). We performed similar experiments with a more aggres-
sive variant of MDA-MB-231—the LM2-4175 cells [31]. Tumors
formed with PDK1 knockdown LM2-4175 cells exhibited an impair-
ment of growth compared to LM2-4175 cells transduced with shScr,
and interestingly, the difference in tumor volume was more pro-
nounced than in MDA-MB-231 wild-type cells (Figure 2B).
To test whether PDK1-dependent inhibition of MDA-MB-231
xenograft growth in vivo was associated with reduced cell proliferation
Figure 1. PDK1 down-regulation reduces anchorage-independent growth and increases apoptosis. MDA-MB-231 and T-47D cells were
transduced with a scramble shRNA (shScr), two separate PDK1-targeting shRNAs (shPDK1#79 and shPDK1#81), or untransduced
(uninfected) and were used for the indicated investigations: (A and B) Protein lysates were obtained and used in immunoblot analysis
for PDK1. Tubulin was used as a loading control. (C and D) Soft agar colony formation assay. Only colonies larger than 100 μm diameter
were counted. (E and F) Apoptosis assay of cells cultured for 24 hours on plastic (gray bar) or maintained in suspension (black). The
number of apoptotic cells was evaluated by using the anti–cytokeratin 18 fragment antibody. *P < .05, **P < .01, ***P < .001.
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Figure 2. PDK1 knockdown impairs tumor formation. (A) MDA-MB-231 or (B) LM2-4175 cells transduced with PDK1-targeting shRNAs
(shPDK1#79 and shPDK1#81) or with a scramble sequence (shScr) were injected subcutaneously in immunodeficient mice. Tumor
weight was evaluated 4 weeks after injection and expressed in milligrams. Red line indicates the average tumor weight. N = number
of mice. (C) Apoptosis within tumors originating from MDA-MB-231 cells, transduced as in A, was evaluated using TUNEL assay, and
representative images are shown in false colors: black/blue, low fluorescence intensity; white, high intensity. Quantification of apopto-
sis (D) and proliferating Ki-67–positive cells (E) in three different regions of tumors as in A. The percentage of apoptotic and proliferating
cells was evaluated in the peripheral, intermediate, and central regions of the tumors. *P < .05, **P < .01, ***P < .001.
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and/or increased apoptosis, tumors were stained with an antibody for
Ki-67 and were subjected to TUNEL assays. Because histologic anal-
yses showed that tumors formed from PDK1-depleted MDA-MB-
231 cells had a larger central necrotic area compared with controls
(Figure 2C ), characterized by high levels of apoptosis, we considered
and quantified the peripheral and intermediate regions of the tumor.
The percentage of apoptotic cells, measured by TUNEL assay, was
significantly higher in tumor silenced for PDK1 compared to those
formed by shScr cells (Figure 2D). Moreover, Ki-67 immunostaining
indicated a decrease in cell proliferation in tumors with reduced PDK1
levels in comparison to MDA-MB-231 cells infected with shScr
(Figures 2E and W2A ). Apparently, the antiapoptotic effect of
PDK1 did not depend on the ability to attract new vessels because
the tumor vascularization level was similar in both tumor types without
any significant decrease in vessel volume and diameter (Figure W2,
B and C ).
Increased PDK1 Potentiates Soft Agar and Tumor Growth
Because it has been shown that PDK1 protein and mRNA are
overexpressed in a majority of human breast cancers, we assessed
the tumorigenic effect of PDK1 overexpression in both MDA-MB-
231 (Figure 3A ) and T-47D (Figure 3B ). The addition of exogenous
PDK1 significantly increased the number of colonies grown in the
soft agar (Figure 3, C and D ). We next determined whether this
in vitro–enhanced tumorigenicity resulted in a tumor growth in-
crease. PDK1-overexpressing MDA-MB-231 cells, subcutaneously
injected in mice, formed tumors with a significantly larger volume
than those of cells transduced with the empty vector (Figure 3E ).
Accordingly, tumors originating from PDK1-overexpressing cells dis-
played a reduced number of apoptotic cells and an increase in pro-
liferating cells, statistically significant only in the central region of the
tumors (Figures 3F and W3, A-C ).
The Kinase Activity of PDK1 Is Required to
Regulate Tumor Growth
To understand the molecular mechanism activated by PDK1 during
anchorage-independent and tumor growth, we investigated which
activity of PDK1 is required for this function. To achieve this purpose,
cells, downregulated for PDK1, were transduced with lentiviral vectors
expressing PDK1 mutants that are insensitive to gene silencing. The
following cDNAs were expressed in MDA-MB-231: PDK1 wild-type
(PDK1), K110N mutant that abolishes kinase activity (PDK1-KD),
and PH domain–deleted mutant that impedes binding to PIP3 at
the membrane (PDK1-ΔPH and PDK1-K465E) (Figures W4A and
W5A). The introduction of PDK1 into silenced cells was able to re-
cover the ability to grow in soft agar, whereas the PDK1-KD was un-
able to rescue the phenotype, suggesting that kinase activity is required
for tumorigenesis. On the contrary, PDK1 mutant in the PH domain
was able to rescue the anchorage-independent growth (Figures 4A
and W5B ). To further support the involvement of PDK1 kinase activ-
ity in soft agar growth and anoikis, we used two kinase inhibitors of
PDK1: BX-795 and OSU-03012. BX-795 inhibited soft agar growth
very effectively (EC50 = 7.78 × 10
−5 M; Figure 4B) and promoted
anoikis (EC50 = 1.46 × 10
−5 M; Figure 4C ). Notably, BX-795 was
much more effective in inducing apoptosis when cells were grown in
the absence of adhesion than when they were plated on plastic (EC50 =
4.82 × 10−5 M; Figure 4C ). Similar results were obtained with OSU-
03012 (Figure W6, A and B). Although these chemical compounds are
not specific inhibitors for PDK1, their EC50 concentration was sensitive
to PDK1 expression levels. In fact, PDK1 silencing sensitized apoptosis
induced by BX-795, by reducing the EC50 to 3.80 × 10
−6 M, whereas
PDK1 overexpression made them more resistant with EC50 = 4.30 ×
10−5M (FigureW6C ). To assess whether the PKD1 kinase activity was
also required for tumor growth, we subcutaneously injected silenced
cells transduced with PDK1 or PDK1-KD. The reintroduction of
PDK1 induced the formation of tumors similar to controls, whereas
the expression of PDK1-KD mutant was totally unable to rescue the
phenotype (Figure 4D ). Furthermore, PDK1 reexpression restored
the percentage of Ki-67–positive cells in the central region of the tumor
(Figure W4B ), whereas it reduced the number of apoptotic cells
(Figure W4C ).
Figure 3. PDK1 overexpression increases anchorage-independent
growth and tumor formation. (A and B) Expression of PDK1 was
evaluated by immunoblot inMDA-MB-231 or T-47D cells transduced
with PDK1 or with an empty vector. Tubulin was used as loading
control. (C and D) Soft agar colony formation assay of MDA-MB-
231 and T-47D cells transduced as indicated in A and B. Only colo-
nies larger than 100 μm diameter were counted. (E) MDA-MB-231
cells transduced as in A were injected subcutaneously in immuno-
deficient mice. Tumor weight was evaluated 4 weeks after injection
and expressed in milligrams (mg). Red line indicates the average
tumor weight. N = number of mice. (F) Quantification of apoptosis
in three different regions of the tumors referring to E. The percent-
age of apoptotic cells was evaluated in the peripheral, intermediate,
and central regions of the tumors. *P< .05, **P< .01, ***P< .001.
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Akt Phosphorylation Is Not Affected by
PDK1 Down-regulation
To further evaluate PDK1 kinase activity arising from reintroduction
of PDK1 mutants, we analyzed Akt1 phosphorylation on Thr308 after
stimulation with hEGF. Unexpectedly, the low levels of PDK1 remain-
ing after gene silencing were still sufficient to phosphorylate Akt at the
same extent of control cells (Figure 5A). However, PDK1 reexpression,
which actually increased PDK1 expression above its physiological levels,
led to an increase in Akt Thr308 phosphorylation, which was prevented
by inactivating mutations in the PDK1 kinase domain (Figure 5A ).
Similar effects were observed on phospho-Ser473 Akt. The Akt phos-
phorylation trend was paralleled by the phosphorylation of Akt down-
stream effectors. PDK1 knockdown was unable to impair the
phosphorylation of both GSK3β and FOXO, and PDK1 overexpres-
sion caused an increased phosphorylation, which was not observed in
cells expressing PDK1 kinase dead (Figure 5A). The addition of PI3K
inhibitor, before the hEGF stimulation, completely abolished both
FOXO and Akt phosphorylation, whereas it was ineffective in inhibit-
ing PDK1 and GSK3β phosphorylation.
Then, we extended the Akt phosphorylation analysis in tumors of
MDA-MB-231 cells. The confocal microscopy analysis revealed that
phosphorylation of Thr308 of Akt was unchanged on PDK1 silenc-
ing. In this case, PDK1 reexpression was unable to increase Akt
phosphorylation in tumors (Figure 5B). However, levels of PDK1
and phospho-Ser241 PDK1 were modest in shPDK1#79 compared
with those in shScr tumors, whereas levels were more evident in
tumors in which PDK1 was reexpressed. In contrast, PDK1-KD
tumors exhibited low levels of PDK1 phosphorylation on Ser241,
as expected in the case of autophosphorylation (Figure 5B) [35].
PDK1 Tumorigenesis Is Akt Independent
Given that PDK1 kinase activity was essential for both cell anchorage–
independent and tumor growth, although its main substrate, Akt,
was not differentially phosphorylated in PDK1 knockdown cells,
we decided to unravel the functional role of Akt in PDK1-mediated
tumorigenesis. The overexpression of Akt1 in MDA-MB-231 did
not increase the fraction of Akt1 phosphorylated on Thr308 both in
PDK1-silenced and control cells. Interestingly, cells with reduced levels
of PDK1 and overexpressing Akt1 showed enhanced Ser473 Akt
phosphorylation. Moreover, the phosphorylation of GSK3β was in-
creased in PDK1-silenced cells, whereas phospho-FOXOwas undetect-
able. Despite these biochemical results, the overexpression of Akt1
(Figure 6A) increased the number of colonies grown in soft agar, but
it was not sufficient to overcome the effect of PDK1 silencing
(Figure 6B). These results suggest that PDK1 and Akt control tumor-
igenesis independently, although the phosphorylation of Thr308 of
Akt by PDK1 has been indicated by several pieces of evidence as the
critical event for Akt activation [4].
Therefore, we tried to rescue the effect of PDK1 silencing with
active Akt mutants, which are independent from the upstream
Figure 4. PDK1 regulates anchorage-independent and tumor growth
by a kinase-dependent mechanism. (A) MDA-MB-231 PDK1 knock-
down cells (shPDK1#79) as in Figure 1 were transduced with vectors
carrying PDK1 wild-type (PDK1), PDK1 kinase-dead (PDK1 KD), PDK1
PH-domain–deleted (PDK1 ΔPH), or empty vectors. PDK1 expres-
sion levels are shown in Figure W4. Soft agar colony formation assay
was performed with the various cell lines and only colonies larger
than 100 μm diameter were counted. (B) Soft agar colony formation
assay with MDA-MB-231 cells was measured in the presence of dif-
ferent concentrations of the PDK1 inhibitor BX-795. EC50 is indicated.
(C) Apoptosis assay with MDA-MB-231 cultured on plastic (gray bar)
or maintained in suspension (black) for 24 hours and treated with
different concentrations (M) of the PDK1 inhibitor BX-795. The num-
ber of apoptotic cells was measured considering the cytokeratin
18 fragment-positive cells and the reported EC50. (D) MDA-MB-231
cells transducedwith scramble shRNA (shScr) or with PDK1-targeting
shRNAs (shPDK1#79) and retransduced with PDK1wild-type (PDK1),
PDK1 kinase-dead (PDK1-KD), or empty vector were injected sub-
cutaneously in immunodeficient mice. Tumor weight was evaluated
4 weeks after injection and expressed in milligrams (mg). Red line
indicates the average tumorweight. *P< .05, **P< .01, ***P< .001.
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Figure 5. PDK1 knockdown does not affect Akt phosphorylation. (A) Immunoblot analysis with the indicated antibodies was performed
on lysates of MDA-MB-231 cells transduced with scramble shRNA (shScr) or PDK1-targeting shRNAs (shPDK1#79) and retransduced
with PDK1 wild-type (PDK1), PDK1 kinase-dead (PDK1-KD), or empty vectors. Cells were treated or not with PI3K inhibitor then stimu-
lated with different concentrations of hEGF. (B) Immunostaining and confocal microscopy analysis of tumor sections originating from
MDA-MB-231 transduced as indicated in A. The images are representatives of four tumors and were acquired with the same confocal
parameters and magnification. Top panels are stained with anti-phosphoPDK1 (pS241PDK1; red) and anti-PDK1 (PDK1; green). Bottom
panels are stained with anti-phosphoAkt (pT308Akt; red) and anti-Akt1 (Akt1; green).
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activators PI3K and PDK1. PDK1-silenced MDA-MB-231 cells were
transduced with retroviruses expressing the constitutive active and
membrane-anchored mutants of Akt1 and Akt2 (myr-Akt1 and myr-
Akt2), the constitutive active mutants in which Thr308 and Ser473
are substituted by Asp mimicking the phosphate required for Akt full
activation (Akt1-DD) and, as control, the kinase-inactive form of
membrane-anchored Akt1 (myr-Akt1-KD; Figure 6C ). Surprisingly,
myr-Akt1 and myr-Akt1-KD did not regulate either GSK3β or FOXO,
although they showed elevated levels of phosphorylation both on
Thr308 and on Ser473. Moreover, the down-regulation of PDK1
did not affect the levels of myr-Akt1 phosphorylation, suggesting that
low levels of PDK1 were not limiting for Akt1 activation. The myr-
Akt2 expression gave similar results despite the low expression levels
we obtained. Instead, Akt1-DD was able to phosphorylate FOXO
but not GSK3β, indicating a substrate selectivity for different Akt1
mutants. The expression of both myr-Akt1 and myr-Akt2 was not able
to rescue the anchorage-independent growth after PDK1 silencing.
Unexpectedly, the Akt1-DD mutant, as well, was not able to compen-
sate the reduced PDK1 activity, although it was able to phosphorylate
FOXO at a level comparable to PDK1 reexpression (Figure 6D).
In contrast, the expression of myr-Akt1 and myr-Akt2 in PDK1-
silenced T-47D cells increased the phosphorylation of GSK3β and
rescued the ability to grow in soft agar (Figure W7).
Differential Effects of Akt and PDK1 Inhibition on
PDK1-Overexpressing Cells
It has been recently demonstrated that PDK1 is overexpressed in
a large proportion of human breast cancers [19]. Therefore, we in-
vestigated the role of Akt in regulating the effects of PDK1 over-
expression in anchorage-independent growth of MDA-MB-231 and
Figure 6. Akt overexpression does not rescue anchorage-independent growth of PDK1 knockdown cells. (A) Immunoblot analysis for the
indicated antibodies was performed on lysates of MDA-MB-231 cells transduced with scramble shRNA (shScr) or with PDK1-targeting
shRNAs (shPDK1#79) and retransduced with Akt1 or empty vectors. β-Actin was used as loading control. (B) Soft agar colony formation
assay performed on MDA-MB-231 cells transduced as indicated. Only colonies larger than 100 μm diameter were counted. (C) Immuno-
blot analysis of lysates of MDA-MB-231 cells transduced with scramble shRNA (shScr) or with PDK1-targeting shRNAs (shPDK1#79)
and retransduced with PDK1 wild-type (PDK1), different active mutants of Akt (myr-Akt1, myr-Akt2, Akt1DD), inactive mutant of Akt (myr-
Akt1 K179M), or empty vectors. (D) Soft agar colony formation assay performed on MDA-MB-231 cells transduced as indicated. Colonies
larger than 100 μm diameter were counted. ***P < .001.
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Figure 7. Akt down-regulation and inhibition does not reduce anchorage-independent growth of PDK1-overexpressingMDA-MB-231. (A and
B) PDK1-overexpressing MDA-MB-231 and T-47D cells were transduced with a scramble shRNA (shScr), two different Akt1 (shAkt1#86
and shAkt1#97) or Akt2 (shAkt2#17 and shAkt2#68) targeting shRNAs, lysed, and analyzed by immunoblot with the indicated antibodies.
(C and D) Soft agar colony formation assay performed onMDA-MB-231 and T-47D cells transduced as indicated above. Only colonies larger
than 100 μm diameter were counted. (E and F) Soft agar colony formation assay of MDA-MB-231 and T-47D cells transduced with PDK1 or
empty vectors and treated with different concentrations of the Akt inhibitor VIII, PDK1 inhibitor, BX-795. EC50 is indicated. (G and H) Soft agar
colony formation assay of MDA-MB-231 and T-47D cells transduced with PDK1 or empty vectors and treated with different concentrations
of PDK1 inhibitor, BX-795. EC50 is indicated. *P < .05, **P < .01, ***P < .001.
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T-47D cells. We stably silenced Akt1 and Akt2 using two different con-
structs per gene in cells overexpressing wild-type PDK1 (Figure 7, A and
B). Down-regulation of both Akt1 and Akt2 did not halt the soft agar
growth of MDA-MB-231 cells (Figure 7C ). However, although Akt1
knockdown was ineffective, the Akt2 silencing inhibited the colony
formation of PDK1-overexpressing T-47D cells (Figure 7D).
Interestingly, treatment with an Akt inhibitor was almost com-
pletely ineffective in blocking the soft agar growth of MDA-MB-
231, in a range of concentration compatible with the reported efficacy
(Figure 7E ), whereas it inhibited T-47D at lower concentrations
(Figure 7F ). In contrast, both T-47D and MDA-MB-231 cells were
sensitive to the PDK1 inhibitor BX-795, but the former responded to
lower concentrations (Figure 7, G and H ). Overexpression of PDK1
shifted the dose-response curve increasing the EC50 in cells treated
with BX-795. These data suggested that MDA-MB-231 are more
sensitive to PDK1 inhibition than T-47D, and this effect is not super-
imposed to that of Akt inhibition.
Discussion
Although only sporadic PDK1mutations have been found in tumors till
now [36], PDK1 has been frequently suggested as a critical component
of the oncogenic PI3K signaling in cancer progression [19,37–40].
In this study, we demonstrate that PDK1 is required for anchorage-
independent growth of breast cancer cells and tumor formation in
mice. The reduction of PDK1 activity by shRNA and chemical inhibi-
tors impairs the soft agar cell growth and sensitizes to apoptosis, par-
ticularly when induced by the absence of anchorage (anoikis).
Nevertheless, the proliferation of adhering breast cancer cells is not
regulated by PDK1. This suggests that PDK1 is involved in the anti-
apoptotic signaling rather than in the mitogenic pathway, in agreement
with previous studies reporting a specific role of PDK1 in cell motility
and invasion but not in proliferation [13,26,32,41].
Other studies have found PDK1 to be involved in the anchorage-
independent growth of cells carrying PIK3CA mutations [19,40].
However, our results demonstrate that breast cancer cells, indepen-
dent of their PIK3CA mutational status, are as well dependent on
PDK1 for in vitro tumorigenesis. Indeed, MDA-MB-231 cells, carry-
ing K-RAS and p53mutations, are more sensitive to PDK1 inhibition
than breast cancer cells harboring PIK3CA mutation, such as T-47D.
In contrast, the inhibition of Akt activity is poorly effective in block-
ing anchorage-independent growth of MDA-MB-231, whereas T-47D
cells exhibit an elevated sensitivity to Akt inhibition. Consistently, Akt
phosphorylation in MDA-MB-231 cells becomes clearly detectable
only on acute stimulation with EGF but not under normal culture con-
ditions, and notably, it does not change after PDK1 silencing both in
cultured cells and in xenograft tumors.
Although the kinase activity of PDK1 has been considered the
unique activity of this enzyme, recent publications spread light to
different mechanisms that are independent from its kinase activity.
PDK1 activates both ROCK1 [13] and Ral-GEF [12] through two
different mechanisms that do not require kinase activity. Never-
theless, in our experimental model, we demonstrate that kinase activ-
ity of PDK1 is required for both anchorage-independent growth and
in vivo tumor formation. The role of kinase domain is further sup-
ported by the results obtained with PDK1 inhibitors that, although
lacking complete specificity for PDK1, inhibit soft agar growth and
sensitize cells to anoikis.
Surprisingly, the PDK1 PH domain, which interact with PIP3
[6,42], is not involved in soft agar growth. Because PDK1 binding
to PIP3 is required for Akt activation [43], these data suggest that
Akt is not involved in PDK1-mediated tumorigenesis. Accordingly,
we found that constitutive active mutants of Akt are not able to rescue
the effects of PDK1 down-regulation on anchorage-independent
growth. Moreover, we show that PDK1 is not a limiting factor for
the phosphorylation of both wild-type and constitutive active Akt
mutants. Actually, residual PDK1 is sufficient to support normal
levels of Thr308 Akt phosphorylation in EGF-stimulated cells, in
agreement with previously published results reporting normal Akt
activation in PDK1-hypomorphic and RNAi-mediated PDK1 knock-
down mice [44,45].
We can conclude that partial inhibition of PDK1 is sufficient to
reduce breast cancer cell soft agar growth even when Akt is normally
activated. Directly related to this conclusion are the results obtained
by PDK1 overexpression. A large fraction of human mammary
tumors have been described to have increased expression of PDK1
caused by gene copy number alteration or epigenetic modulations
[19]. However, it is largely unknown which mechanisms involved
in cancer progression are activated by PDK1. Our results suggest that
Akt is not the main substrate activated in this process because the
effects of PDK1 overexpression are not affected by Akt knockdown
or enzymatic inhibition. Currently, the nature of PDK1 substrate
involved in the tumorigenic process remains elusive and requires fur-
ther studies focused on its identification.
Several studies suggest PDK1 as an oncology target; however, they
do not provide a definitive assessment of the targeting efficacy of
PDK1. The in vivo pharmacological inhibition of PDK1 remains a
challenge for the poor selectivity of existing drugs [26,46,47]. Instead,
the genetic approaches produced strong evidence about the role of
PDK1 in PTEN-driven tumor progression. PDK1 hypomorphic mice,
which express low levels of PDK1, when crossed to PTEN+/− mice
suppress PTEN-driven tumorigenesis [37]. Unexpectedly, a recent
report demonstrated a lack of antitumor efficacy by RNAi-mediated
long-term PDK1 knockdown in different mouse models of PTEN-
deficient cancer [45]. Notably, all these results have been obtained in
tumor models dependent on PTEN deficiency. Here, we show that
PDK1 is required for experimental tumor formation in the absence
of any alteration of PI3K pathway. BothMDA-MB-231 parental breast
cancer cells and their highly metastatic variant, LM2-4175 [31], are
dependent on PDK1 for tumor growth in mouse. Therefore, the com-
mon idea of PDK1 as a potential therapeutic target in tumors with
altered regulation of PI3K signaling should be overcome. Consistently,
reduced levels of PDK1 are still sufficient to phosphorylate Akt in our
experimental tumors, suggesting its involvement in other signaling
pathways. This hypothesis is also supported by recent results report-
ing that the inhibition of PDK1 abrogates the rapamycin resistance
of colon cancer in a PI3K and Akt-independent manner but anyhow
dependent on its kinase activity [30]. Notably, by reexpression of
kinase-dead mutants, we clearly demonstrate that the phosphoryla-
tion ability of PDK1 is required for experimental tumor formation.
Then, our results strongly support the efforts to discover specific PDK1
inhibitors and to develop the existing ones for preclinical studies in tumor
models [48–50].
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Figure W1. PDK1 knockdown does not affect proliferation of breast cancer cells but increases apoptosis induced by the absence of
anchorage. (A and B) Proliferation of the indicated cells plated on plastic dishes was evaluated as cell numbers at the indicated time
points. MDA-MB-231 (A) and T-47D (B) cells were transduced with a scramble shRNA (shScr), two separate shRNAs targeting PDK1
(shPDK1#79 and shPDK1#81), or left untransduced (uninfected). (C and D) Apoptosis index of the indicated cells cultured on plastic
dishes or maintained in suspension and evaluated by quantifying mononucleosomes and oligonucleosomes. Cells were transduced
with a scramble shRNA (shScr), normalized to 1 and compared to cells transduced with shPDK1#79. (E and F) Apoptosis assay of
MDA-MB-231 and T-47D transduced as indicated above. Cells were cultured for 48 hours in the presence or absence of fetal calf serum.
The percentage of apoptotic cells was evaluated by analyzing the presence of cytokeratin 18 fragment. *P < .05, **P < .01, ***P < .001.
Figure W2. Angiogenesis is not impaired in tumors originating from PDK1-silenced MDA-MB-231 cells. (A) MDA-MB-231 transduced
with shRNA targeting PDK1 (shPDK1) or a scramble sequence (shScr) were injected subcutaneously in immunodeficient mice. Tumors
were evaluated 4 weeks after injection. Cell proliferation and angiogenesis in the peripheral, intermediate, and central regions of tumors
were evaluated in immunofluorescence using an anti–Ki-67 (red) or an anti-CD31 (green) antibody, respectively. Pictures are represen-
tative of four different tumors. (B and C) Quantification of angiogenesis in three different tumor regions by calculating the vessel volume
compared with the overall tumor mass (B) and by measuring the mean vessel diameter (C).
Figure W3. PDK1 overexpression reduces apoptosis and increases cell proliferation in the experimental tumor. (A) Apoptosis within
tumors originating from MDA-MB-231 transduced with PDK1 or empty vector was evaluated with TUNEL assays. Representative pic-
tures of three different tumor regions are shown in false colors: black/blue, low fluorescence intensity; white, high intensity. (B) Cell
proliferation in the peripheral, intermediate, and central regions of tumors was evaluated in immunofluorescence using an anti–Ki-67
(red) and (C) quantified as Ki-67–positive cell percentage. *P < .05, **P < .01, ***P < .001.
Figure W4. PDK1 regulates proliferation and apoptosis in experi-
mental tumors in a kinase-dependent manner. (A) The expression
of PDK1 was evaluated in PDK1-knockdown cells (shPDK1#79)
transduced with vectors carrying PDK1 wild-type (PDK1), PDK1
kinase-dead (PDK1 KD), PDK1 PH domain–deleted (PDK1 ΔPH),
PDK1 mutated in the PIF-pocket (PDK1 L155E), PDK1 with deletion
of 50C-terminusaminoacids (PDK1Δ50) or empty vector by immuno-
blot. Tubulinwas usedas a loadingcontrol. (B andC)Quantification of
cell proliferation and apoptosis within tumors originating from MDA-
MB-231 transduced with scramble shRNA (shScr) or with shRNAs
targeting PDK1 (shPDK1#79) and retransduced with PDK1 wild-type
(PDK1), PDK1 kinase-dead (PDK1-KD), or empty vector. The percent-
age of Ki-67–positive (B) or TUNEL-positive cells (C) was reported.
Figure W5. PDK1 mutant in the PH domain rescues anchorage-independent growth. MDA-MB-231 PDK1-knockdown cells (shPDK1#79)
as in Figure 1 were transduced with vectors carrying PDK1 mutant in the PH domain (PDK1-K465E) or empty vectors. (A) PDK1 expres-
sion levels are shown by immunoblot analysis. (B) Soft agar colony formation assay was performed with the indicated cell lines. Col-
onies larger than 100 μm diameter were counted. ***P < .001.
Figure W6. OSU-03012 blocks anchorage-independent growth of MDA-MB-231 and promotes anoikis. (A) Soft agar colony formation
assay of MDA-MB-231 treated with different concentrations of PDK1 inhibitor OSU-03012. EC50 is indicated. (B) Apoptosis assay of
MDA-MB-231 treated with different concentrations of PDK1 inhibitor, OSU-03012. The number of apoptotic cells was evaluated using
anti–cytokeratin 18 fragment antibody, and EC50 is reported. (C) Apoptosis assay of MDA-MB-231 transduced with empty vector, PDK1,
or shPDK1 and treated with different concentrations of PDK1 inhibitor, BX-795. The number of apoptotic cells was evaluated using anti–
cytokeratin 18 fragment antibody, and EC50 is reported.
Figure W7. Myr-Akt expression rescues anchorage-independent
growth of PDK1 knockdown in T-47D cells. (A) Immunoblot analy-
sis of lysates of T-47D cells transduced with scramble shRNA
(shScr) or with PDK1-targeting shRNAs (shPDK1#79) and retrans-
duced with PDK1 wild-type (PDK1), different active mutants of Akt
(myr-Akt1, myr-Akt2, Akt1DD), inactive mutant of Akt (myr-Akt1
K179M), or empty vectors. (B) Soft agar colony formation assay
performed on T-47D cells transduced as indicated. Colonies larger
than 100 μm diameter were counted. ***P < .001.
